In the study, musculoskeletal side effects were more common under lebrikizumab than under [[placebo]] (13.2% versus 5.4%). Other side effects were comparable in both groups: infections overall 48.1% versus 49.1%, upper airway infections 12.3% versus 14.3%, and severe side effects overall 3.8% (treatment) versus 5.3% (placebo).<ref name="Corren" />

 

